other material
confidence high
sentiment positive
materiality 0.80
Evommune's EVO301 hits Phase 2a primary endpoint in atopic dermatitis: 55% EASI reduction vs 22% placebo
Evommune, Inc.
- Phase 2a trial (n=70; 48 active, 22 placebo) of IV EVO301 5mg/kg at Baseline and Week 4 met its primary endpoint: 55% LS mean EASI reduction at Week 12 vs 22% on placebo (p<0.01).
- EASI-50 at Week 12 was 63% for EVO301 vs 23% placebo; EASI-75 was 29% vs 9%; separation appeared by Week 4 (41% vs 18%) and held through Week 8 (50% vs 16%).
- Safety: no treatment-related serious or severe adverse events, no discontinuations, no conjunctivitis; treatment-related AEs in 10.4% of EVO301 patients vs 13.6% on placebo.
- Biomarkers: ~75% reduction in CCL-17 (TARC) in patients with high baseline TARC, with reductions also in CCL-22, IL-22 and Th1/Th17/Th22 pathway markers.
- Subcutaneous Phase 2b dose-ranging trial on track to begin mid-2027; PK profile supports Q4-week dosing with potential every-8-to-12-week maintenance.